Skip to content

A randomized, double-blind multicenter clinical study on Qing-Huo-Rou-Gan-Ming-Mu-Fang treat the uveitis (VKH syndrome-syndrome of burning-heat in the liver and gallbladder)

A randomized, double-blind multicenter clinical study on Qing-Huo-Rou-Gan-Ming-Mu-Fang treat the uveitis (VKH syndrome-syndrome of burning-heat in the liver and gallbladder )

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17013390
Enrollment
Unknown
Registered
2017-11-15
Start date
2017-11-20
Completion date
Unknown
Last updated
2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uveitis

Interventions

one:Qing-Huo-Rou-Gan-Ming-Mu-Fang

Sponsors

Affiliated Eye Hospital, Shandong University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Diagnostic criteria for VKH syndrome; TCM syndrome is consistent with the syndrome of burning-heat in the liver and gallbladder; Other systemic diseases such as diabetes, hypertension, coronary heart disease, rheumatism, etc are stable; Aged between 18 and 70 years old; Other medications have been used, but the drug has been stopped for more than 2 weeks; Informed consent.;Inclusion criteria: Diagnostic criteria for VKH syndrome; TCM syndrome is consistent with the syndrome of burning-heat in the liver and gallbladder; Other systemic diseases such as diabetes, hypertension, coronary heart disease, rheumatism, etc are stable; Aged between 18 and 70 years old; Other medications have been used, but the drug has been stopped for more than 2 weeks; Informed consent.

Exclusion criteria

Exclusion criteria: 1) combine glaucoma, optic nerve disease and various fundus lesions, such as retinal detachment, retinal vein occlusion, retinal pigment degeneration, blood or vascular disease; 2) combined with ocular infection or combined with cornea, iris, obvious lens lesion; 3) it is necessary to use drugs that improve circulation and nutrient nerves, and cannot be stopped in the short term; 4) planned any eye surgery or laser treatment; 5) known or suspected to have a history of allergy or serious adverse reactions to test drugs, or those with allergies; 6) with high blood pressure, but by the drugs treatment the blood pressure is still high (systolic =160mmHg or diastolic = 100mmHg); with severe cardiopulmonary insufficiency or severe heart rhythm disorders ; 7) patients with severe liver and kidney disorders; Among them, the hepatic power damage ALTAST > normal value of 1.5 times; Blood creatinine (Cr) is higher than normal value; 8) patients with severe diabetes mellitus, advanced tumors, and/or other systemic or progressive diseases; 9) the combination of neurologic and mental disorders can not cooperate or unwillingness to cooperate; 10) pregnant, lactating women or recent family planning; 11) the researcher considers that it is not appropriate to participate in other situations in this experiment; 12) participating in other clinical trials.;Exclusion criteria: 1) combine glaucoma, optic nerve disease and various fundus lesions, such as retinal detachment, retinal vein occlusion, retinal pigment degeneration, blood or vascular disease; 2) combined with ocular infection or combined with cornea, iris, obvious lens lesion; 3) it is necessary to use drugs that improve circulation and nutrient nerves, and cannot be stopped in the short term; 4) planned any eye surgery or laser treatment; 5) known or suspected to have a history of allergy or serious adverse reactions to test drugs, or those with allergies; 6) with high blood pressure, but by the drugs treatment the blood pressure is still high (systolic =160mmHg or diastolic = 100mmHg); with severe cardiopulmonary insufficiency or severe heart rhythm disorders ; 7) patients with severe liver and kidney disorders; Among them, the hepatic power damage ALTAST > normal value of 1.5 times; Blood creatinine (Cr) is higher than normal value; 8) patients with severe diabetes mellitus, advanced tumors, and/or other systemic or progressive diseases; 9) the combination of neurologic and mental disorders can not cooperate or unwillingness to cooperate; 10) pregnant, lactating women or recent family planning; 11) the researcher considers that it is not appropriate to participate in other situations in this experiment; 12) participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Vitreous turbidity;Dosage of hormone;;Vitreous turbidity;Dosage of hormone;

Countries

China

Contacts

Public ContactBi Hongsheng;Bi Hongsheng ;

Affiliated Eye Hospital, Shandong University of Traditional Chinese Medicine;Affiliated Eye Hospital, Shandong University of Traditional Chinese Medicine

hongshengbi1@163.com;hongshengbi1@163.com+86 13064079007;+86 13064079007

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026